| 2025-11-06 |
详情>>
内部人交易：
BARRY JAMES股份减少699.87股
|
| 2025-10-29 |
详情>>
股本变动：
变动后总股本2697.48万股
|
| 2025-10-29 |
详情>>
业绩披露：
2025年三季报(累计)每股收益1.46美元,归母净利润3990.00万美元,同比去年增长103.54%
|
| 2025-10-29 |
财报披露：
美东时间 2025-10-29 盘后发布财报
|
| 2025-07-31 |
详情>>
业绩披露：
2025年中报每股收益13.84美元,归母净利润3.82亿美元,同比去年增长121.43%
|
| 2025-05-01 |
详情>>
业绩披露：
2025年一季报每股收益2.29美元,归母净利润6400.00万美元,同比去年增长-83.33%
|
| 2025-03-26 |
股东大会：
将于2025-04-22召开股东大会
会议内容 ▼▲
- 1.The election of two directors by the holders of outstanding Class A Common Stock and four directors by the holders of outstanding Class B Common Stock;
2.A proposal to ratify the selection of KPMG LLP as our independent auditors for the fiscal year ending December 31, 2025;
3.A stockholder proposal requesting approval of certain executive severance arrangements, if properly presented at the annual meeting;
4.Such other matters as may properly come before the meeting and at any adjournments or postponements thereof.
|
| 2025-02-14 |
详情>>
业绩披露：
2024年年报每股收益-65.36美元,归母净利润-18.44亿美元,同比去年增长-189.37%
|
| 2025-02-14 |
详情>>
业绩披露：
2022年年报每股收益-121.79美元,归母净利润-36.27亿美元,同比去年增长-185.27%
|
| 2024-10-31 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-39.89美元,归母净利润-11.28亿美元,同比去年增长-14.32%
|
| 2024-08-02 |
详情>>
业绩披露：
2023年中报每股收益-37.09美元,归母净利润-10.93亿美元,同比去年增长74.53%
|
| 2024-08-02 |
详情>>
业绩披露：
2024年中报每股收益-62.61美元,归母净利润-17.82亿美元,同比去年增长-62.96%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益13.46美元,归母净利润3.84亿美元,同比去年增长456.71%
|
| 2024-03-27 |
股东大会：
将于2024-04-23召开股东大会
会议内容 ▼▲
- 1.Election of Directors
2.Ratification of Auditors
3.Approval of the amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan
|
| 2024-02-16 |
详情>>
业绩披露：
2023年年报每股收益-21.82美元,归母净利润-6.37亿美元,同比去年增长82.43%
|
| 2023-10-27 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-33.63美元,归母净利润-9.87亿美元,同比去年增长77.85%
|
| 2023-03-29 |
股东大会：
将于2023-04-25召开股东大会
会议内容 ▼▲
- 1.The election of two directors by the holders of outstanding Class A Common Stock and four directors by the holders of outstanding Class B Common Stock;
2.A proposal to ratify the selection of KPMG LLP as our independent auditors for the fiscal year ending December 31, 2023;
3.An advisory (non-binding) vote to approve executive compensation;
4.An advisory (non-binding) vote on the frequency of future advisory votes to approve executive compensation every 1, 2 or 3 years;
5.A stockholder proposal, if properly presented at the annual meeting;
6.Such other matters as may properly come before the meeting and at any adjournments or postponements thereof.
|
| 2022-03-30 |
股东大会：
将于2022-04-26召开股东大会
会议内容 ▼▲
- 1.The election of two directors by the holders of outstanding Class A Common Stock and four directors by the holders of outstanding Class B Common Stock;
2.A proposal to ratify the selection of KPMG LLP as our independent auditors for the fiscal year ending December 31, 2022;
3.Such other matters as may properly come before the meeting and at any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-31 |
股东大会：
将于2021-04-27召开股东大会
会议内容 ▼▲
- 1.The election of two directors by the holders of outstanding Class A Common Stock and four directors by the holders of outstanding Class B Common Stock;
2.A proposal to ratify the selection of KPMG LLP as our independent auditors for the fiscal year ending December 31, 2021;
3.Such other matters as may properly come before the meeting and at any adjournments or postponements thereof.
|
| 2020-04-01 |
股东大会：
将于2020-04-28召开股东大会
会议内容 ▼▲
- 1.The election of two directors by the holders of outstanding Class A Common Stock and four directors by the holders of outstanding Class B Common Stock;
2.A proposal to ratify the selection of KPMG LLP as our independent auditors for the fiscal year ending December 31, 2020;
3.An advisory (non-binding) vote to approve executive compensation;
4.Such other matters as may properly come before the meeting and at any adjournments or postponements thereof.
|
| 2019-04-04 |
股东大会：
将于2019-04-29召开股东大会
会议内容 ▼▲
- 1.The election of two directors by the holders of outstanding Class A Common Stock and four directors by the holders of outstanding Class B Common Stock;
2.A proposal to ratify the selection of KPMG LLP as our independent auditors for the fiscal year ending December 31, 2019;
3.Such other matters as may properly come before the meeting and at any adjournments or postponements thereof.
|
| 2018-05-04 |
股东大会：
将于2018-06-14召开股东大会
会议内容 ▼▲
- 1.The election of two directors by the holders of outstanding Class A Common Stock and four directors by the holders of outstanding Class B Common Stock;
2.A proposal to ratify the selection of KPMG LLP as our independent auditors for the fiscal year ending December 31, 2018;
3.Such other matters as may properly come before the meeting and at any adjournments or postponements thereof.
|
| 2017-03-30 |
股东大会：
将于2017-04-25召开股东大会
会议内容 ▼▲
- 1.The election of two directors by the holders of outstanding Class A Common Stock and four directors by the holders of outstanding Class B Common Stock;
2.A proposal to ratify the selection of KPMG LLP as our independent auditors for the fiscal year ending December 31, 2017;
3.A proposal to approve the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan;
4.A proposal to approve an amendment to the Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan to increase the number of shares authorized for sale thereunder by 700,000;
5.An advisory (non-binding) vote to approve executive compensation;
6.An advisory (non-binding) vote on the frequency of holding future advisory votes to approve executive compensation every 1, 2 or 3 years;
7.Such other matters as may properly come before the meeting and at any adjournments or postponements thereof.
|
| 2016-03-31 |
股东大会：
将于2016-04-26召开股东大会
会议内容 ▼▲
- 1.The election of two directors by the holders of outstanding Class A Common Stock and four directors by the holders of outstanding Class B Common Stock
2.A proposal to ratify the selection of KPMG LLP as our independent auditors for the fiscal year ending December 31, 2016;
3.A stockholder proposal, if properly presented at the annual meeting;
4.Such other matters as may properly come before the meeting and at any adjournments or postponements thereof.
|